30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

1Q13 Revenue: Anika Therapeutics

$11.2MM, +12% (U.S. +12%, ex-U.S. +9%)

  • Growth reflects marketing and sales investments from partner, DePuy Mitek, to support awareness of ORTHOVISC
  • Ex-U.S. viscosupplementation sales soft primarily due to reimbursement, country-specific issues
  • Assigned ORTHOVISC and MONOVISC distribution in Canada to Pharmascience
  • Submitted a proposal to FDA for a “parallel path” strategy for MONOVISC in case the Premarket Approval amendment doesn’t work out
  • Single-injection segment doesn’t appear to be hurting ORTHOVISC sales